<div id="readability-page-1"><div>NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against RxSight, Inc. (“RxSight” or the “Company”)(NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether RxSight and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until September 22, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired RxSight securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com. [Click here for information about joining the class action] On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, revealing significant declines in Light Delivery Device (“LDD”) sales, light adjustable intraocular lenses utilization, and overall revenue. The Company also lowered its full year 2025 guidance by approximately $42.5 million at the midpoint. RxSight’s Chief Executive Officer, Ronald Kurtz, disclosed that “[a] doption challenges over the last few quarters have been a primary reason for the LDD stall.” On this news, RxSight’s stock price fell $4.84 per share, or 37.84%, to close at $7.95 per share on July 9, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP dpeyton@pomlaw.com 646-581-9980 ext. 7980 <img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVd09ESXpOeU0zTURnM056a3lJekl3TVRjMk5EUT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVd09ESXpOeU0zTURnM056a3lJekl3TVRjMk5EUT0"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2M2YWVkZmItYWE3My00MzY3LWJmNjItMjk5NmE5YzYwNGZhLTEwMjkyMTctMjAyNS0wOC0wOS1lbg==/tiny/Pomerantz-LLP.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2M2YWVkZmItYWE3My00MzY3LWJmNjItMjk5NmE5YzYwNGZhLTEwMjkyMTctMjAyNS0wOC0wOS1lbg==/tiny/Pomerantz-LLP.png"/></div></div>

RXST

Pomerantz 律師事務所已對 RxSight, Inc.（納斯達克代碼：RXST）提起集體訴訟，指控其涉嫌證券欺詐。遭受損失的投資者被鼓勵在 2025 年 9 月 22 日之前聯繫該事務所，以申請成為首席原告。此次訴訟是由於 RxSight 在 2025 年第二季度的業績令人失望，銷售額大幅下降，全年指導預期減少 4250 萬美元，導致股價下跌 37.84%。Pomerantz LLP 專注於公司和證券集體訴訟

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RxSight, Inc. of Class Action Lawsuit and Upcoming Deadlines - RXST

投資者警示：Pomerantz 律師事務所提醒在 RxSight, Inc.投資中遭受損失的投資者注意集體訴訟及即將到來的截止日期 - RXST